Thiel E - Search Results

1

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C. Nagorsen D, et al. Among authors: thiel e. Cancer Res. 2000 Sep 1;60(17):4850-4. Cancer Res. 2000. PMID: 10987297

2

Rational peptide-based tumour vaccine development and T cell monitoring.

Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: thiel e. Semin Cancer Biol. 2003 Dec;13(6):423-9. doi: 10.1016/j.semcancer.2003.09.006. Semin Cancer Biol. 2003. PMID: 15001161 Review.

3

Immunological monitoring of cancer vaccine therapy.

Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Nagorsen D, et al. Among authors: thiel e. Expert Opin Biol Ther. 2004 Oct;4(10):1677-84. doi: 10.1517/14712598.4.10.1677. Expert Opin Biol Ther. 2004. PMID: 15461579 Review.

4

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.

Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: thiel e. Int J Cancer. 2005 May 10;114(6):936-41. doi: 10.1002/ijc.20819. Int J Cancer. 2005. PMID: 15645483 Clinical Trial.

5

Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).

Asemissen AM, Scheibenbogen C, Letsch A, Hellstrand K, Thorén F, Gehlsen K, Schmittel A, Thiel E, Keilholz U. Asemissen AM, et al. Among authors: thiel e. Clin Cancer Res. 2005 Jan 1;11(1):290-7. Clin Cancer Res. 2005. PMID: 15671558 Clinical Trial.

6

Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.

Nagorsen D, Thiel E. Nagorsen D, et al. Among authors: thiel e. Clin Cancer Res. 2006 May 15;12(10):3064-9. doi: 10.1158/1078-0432.CCR-05-2788. Clin Cancer Res. 2006. PMID: 16707603

7

Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.

Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C. Asemissen AM, et al. Among authors: thiel e. Clin Cancer Res. 2006 Dec 15;12(24):7476-82. doi: 10.1158/1078-0432.CCR-06-1337. Clin Cancer Res. 2006. PMID: 17189421

8

HLA-A2 expression, stage, and survival in colorectal cancer.

Kiewe P, Mansmann V, Scheibenbogen C, Buhr HJ, Thiel E, Nagorsen D. Kiewe P, et al. Among authors: thiel e. Int J Colorectal Dis. 2008 Aug;23(8):767-72. doi: 10.1007/s00384-008-0488-y. Epub 2008 May 7. Int J Colorectal Dis. 2008. PMID: 18461337

9

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.

Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D. Scheibenbogen C, et al. Among authors: thiel e. Int J Cancer. 2002 Mar 20;98(3):409-14. doi: 10.1002/ijc.10205. Int J Cancer. 2002. PMID: 11920592

10

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.

Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: thiel e. Int J Cancer. 2002 May 20;99(3):403-8. doi: 10.1002/ijc.10328. Int J Cancer. 2002. PMID: 11992409

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

792 results

Search Page

Filters